SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to mixed market reactions following its Q4 earnings beat, as the stock experiences a significant dip despite exceeding revenue and EPS estimates. Community discussion centers on concerns over decelerating subscriber growth and conservative 2026 guidance, alongside the ongoing drama and shareholder sentiment surrounding the proposed Warner Bros. acquisition and its impact on buybacks and future debt.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of exceptionally high-grade silver drill results from its Nevada project and a broader surge in precious metals prices. The community is actively discussing continued accumulation by billionaire investor Eric Sprott and the potential for a significant short squeeze, while also noting recent commentary from CEO Diane Garrett regarding the company's capital position. Despite enthusiasm for its vast resources, some caution against its current lack of commercial production amid a rapidly rising valuation.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid significant business developments, including an expanded multi-year, multi-hundred-million-dollar deal with HD Hyundai and prominent features at Davos showcasing its AI platform's efficiency. Community discussion is polarized between excitement over its AI-driven revenue growth and skepticism concerning its high valuation, alongside recent controversial reports about its work with government agencies like ICE. The company's unique position at the intersection of AI, government, and enterprise continues to fuel intense debate on its ethical implications and future growth trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing a sharp downturn as natural gas prices surge due to "mega bullish" cold weather forecasts and an anticipated "short squeeze" in long natural gas positions. The community is actively debating whether to buy KOLD on its significant dip, anticipating a potential reversal in what many perceive as overbought natural gas. Traders are navigating extreme volatility and the inherent decay of these leveraged ETFs, closely watching for further shifts in weather patterns and market sentiment for this "widowmaker" commodity.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending following news of a significant public offering coupled with a strategic private placement where Medtronic agreed to acquire a substantial stake, alongside the initiation of its pivotal PARADIGM trial for the DurAVR heart valve. While some investors are expressing concerns about share dilution, a strong bullish sentiment persists within the community, citing institutional interest and the potential for a major re-rating given the advanced stage of its medical device technology.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to recent significant government contract wins, notably with the U.S. Department of Health and Human Services and the U.S. Army, signaling increasing adoption of its enterprise AI solutions within the public sector. The community is actively debating whether these new contracts, combined with its high short interest and new leadership, position the company for a major turnaround despite past financial concerns and ongoing skepticism about its long-term growth trajectory.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its eczema drug, soquelitinib, which showed significant efficacy and safety, particularly in treatment-resistant patients. This promising development has fueled speculation about its blockbuster potential and future partnerships, even as the company's recent public offering sparks debate among investors regarding potential dilution versus funding for accelerated pipeline progression. The community is actively discussing the drug's strong profile and the ongoing battle between bulls and bears as the stock experiences substantial volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative of Rage Comics, positioning it as a foundational meme reset for the current market cycle. This dedicated base actively builds an ecosystem with platforms like RageMaker and RageGames, expressing strong conviction and urging fellow enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 4,951,552...

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving Average - Time to Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above 50-Day Moving Average - Here's Why...

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving Average - Should You Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above 50 Day Moving Average - What's Next...

Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...

<ul class="summary-bullets"><li>The FDA delayed its decision on the dry eye drug Reproxalap without raising new issues.</li><li>The FDA pushed the PDUFA deadline to March 16, 2026, after requesting a clinical study report already reviewed under an earlier filing.</li><li>Regulatory progress continued, with the FDA sharing a draft label and outlining next steps.</li></ul>Aldeyra Therapeutics shares jumped on Tuesday, heading for their best day in more than eight months, after the U.S. Food and Drug Administration (FDA) extended its review of the company’s dry eye drug without flagging any new issues.The stock rose 31% to hit $5.22 at the time of writing.<h2 class="st-heading-2">FDA Timeline</h2>Aldeyra Therapeutics said the FDA has pushed back its decision deadline on Reproxalap, the company’s dry eye drug, to March 16, 2026. The deadline, known as the Prescription Drug User Fee Act target action date, had previously been set for Dec. 16.The extension follows a Dec. 12 meeting between the FDA and the company, during which the agency requested submission of a Clinical Study Report for a dry eye disease field trial. Aldeyra said the report was submitted to the NDA on the same day and was classified by the FDA as a major amendment, triggering the three-month extension.<h2 class="st-heading-2">Scope Of The FDA Request</h2>The company said the FDA made no other requests at the December meeting and did not identify any additional issues with the NDA review. The Clinical Study Report had already been reviewed by the FDA under the drug’s Investigational New Drug file.Aldeyra also said safety data from the field trial had been submitted earlier, in August, at the FDA’s request during the NDA review process.The field trial, for which top-line results were announced in May, did not meet its primary endpoint of improving dry eye symptoms compared with a vehicle control. The company said the trial was supportive of the activity of the drug relative to the vehicle and had been discussed with the FDA before the NDA submission.<h2 class="st-heading-2">Labeling Progress&nbsp;</h2>Earlier this month, the FDA shared a draft of the proposed label for the dry eye drug with Aldeyra, and the company said it has submitted a response. According to Aldeyra, the FDA indicated that if no major deficiencies are identified during the extended review period, the agency plans to communicate proposed labeling requests and any anticipated postmarketing requirements by Feb. 16, 2026.Aldeyra said the NDA was originally submitted on June 16, and was accepted for review as a complete class 2 response in July.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Aldeyra was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/136;" src="https://news.stocktwits-cdn.com/aldx_ss_png_1199f19110.webp" alt="aldx ss.png" width="972" height="136"><figcaption>ALDX sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure>One bullish user expects the stock to “keep rising during the day.”<stembedurl>https://stocktwits.com/MUBSN/message/639307502</stembedurl>Another user said, “Abbvie buy this bad boy out!”<stembedurl>https://stocktwits.com/GhostLegend/message/639301686</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra’s stock</a> has risen 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Equity

683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX

Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...

Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX

Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALDX News

ALDXAldeyra Therapeutics Inc